About Contact Us Careers
Sign In

Non-Metastatic Castration Resistant Prostate Cancer Treatment Market - Top Companies and Manufacturers

  • Report ID: 2884
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Companies Dominating the Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Astellas Pharma Inc.
    • Clovis Oncology, Inc.
    • Johnson & Johnson Health Care Systems Inc.
    • Bayer AG
    • Orion Corporation
    • Merck & Co., Inc.
    • Novartis AG
    • AstraZeneca PLC
Browse Key Market Insights with Data Illustration:

In the News

  • Astellas Pharma Inc. to conduct clinical trials to develop cell therapy. The development pipeline of the company includes high unmet medical needs such as autoimmune & cardiovascular diseases and cancer. The cell therapy research of the company is based on pluripotent stem cells (PSC)

  • Clovis Oncology, Inc. to present data from Phase 3 trial, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy inmCRPC Associated with Homologous Recombination Deficiency (HRD)”. The trial is associated with men with metastatic castration-resistant prostate cancer.


Author Credits:  Radhika Pawar


  • Report ID: 2884
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 7.64 Billion.

The non-metastatic castration resistant prostate cancer treatment market size was over USD 7.33 Billion in 2023 and is poised to cross USD 13.32 Billion by the end of 2036, witnessing more than 4.7% CAGR during the forecast period i.e., between 2024-2036. Growing prevalence of prostate cancer and growth in the investment and R&D activities in oncology are the major factors driving the market growth.

North America is predicted to dominate majority industry share by 2036, propelled by increasing awareness about nmCRPC and the need to develop innovative cancer treatment solutions in the region.

Pfizer Inc., Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample